Sign in

Research summary ·

Lithium-associated hyperparathyroidism: a systematic review of prevalence and surgical outcomes.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This review looked at high calcium and overactive parathyroid glands in people who take lithium. This is called lithium-associated hyperparathyroidism (LHPT). Lithium is a long-term drug for bipolar disorder. The team followed PRISMA guidelines and searched several databases. It found 5,483 records, and 125 studies met the inclusion criteria. Surgical case series were analysed separately.

What they found

Hypercalcemia occurred in 423 of 5,853 lithium-treated people. Hyperparathyroidism was confirmed in 156 of 3,239. Multiglandular disease was found in many surgical cases. It was substantially more common than in sporadic HPT. Most surgical series used bilateral neck exploration. Success rates after surgery varied widely. Recurrence was also reported over 10 years.

What it means for patients

The paper says LHPT is a significant hormone complication. It says multiglandular disease matters for surgical planning. It says surgeons should keep a low bar for exploring both sides of the neck.

Why it is not certain yet

The paper says how common LHPT is was not fully defined. The same holds for its causes and the ideal surgical approach. Results after surgery ranged widely between series. A review can only be as good as the studies in it.

Source

Lithium-associated hyperparathyroidism: a systematic review of prevalence and surgical outcomes.

PubMed · PMID 42606582

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Bipolar disorder publications